CommercialCoverageHigh impact
Gemcitabine (CPB 0958, reviewed 2026-07-17)
Aetna·Oncology, Hematology, Radiation Oncology·Medical Policy
We identified it
Aug 15, 2026
Summary
Aetna updated its Gemcitabine (CPB 0958) clinical policy bulletin for commercial medical plans, establishing comprehensive coverage criteria for 30+ cancer indications including breast, ovarian, pancreatic, lung, and lymphoma cancers. The policy specifies approved dosing regimens for major indications and clarifies that gemcitabine is considered experimental/investigational for all other uses. Billing teams must verify patient diagnoses match approved indications and use appropriate HCPCS codes (J9184, J9196, J9201) for claims to be covered.
Action Required
IMMEDIATE: Billing team must update claim submission protocols to validate that all gemcitabine claims include ICD-10 diagnosis codes matching Aetna's approved indications list (Section I criteria). For claims with diagnoses NOT on the approved list, deny internally or flag for prior authorization review, as Aetna considers these experimental/investigational. Update billing software logic to cross-reference submitted ICD-10 codes (C00.0-C96.9 range and specific lymphoma codes) against the approved indications. Verify chemotherapy administration codes (96413-96417) are billed with approved HCPCS gemcitabine codes (J9184, J9196, J9201). Train billing staff on the 30+ covered indications before processing claims. Failure to validate diagnosis coverage will result in claim denials for off-label or investigational uses.